LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Microbot Medical Inc

Fechado

2.03 -5.14

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.99

Máximo

2.14

Indicadores-chave

By Trading Economics

Rendimento

-77K

-3.6M

Funcionários

20

EBITDA

-79K

-3.6M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+264.08% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.4M

146M

Abertura anterior

7.17

Fecho anterior

2.03

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Microbot Medical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de fev. de 2026, 22:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 de fev. de 2026, 22:36 UTC

Ganhos

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 de fev. de 2026, 22:32 UTC

Ganhos

Woodside Energy Fiscal Year Net Profit Falls 24%

23 de fev. de 2026, 23:58 UTC

Conversa de Mercado
Ganhos

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 de fev. de 2026, 23:58 UTC

Conversa de Mercado
Ganhos

Global Energy Roundup: Market Talk

23 de fev. de 2026, 23:47 UTC

Conversa de Mercado

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 de fev. de 2026, 23:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Crescent Capital Partners Owns 53% of ClearView Wealth

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 de fev. de 2026, 23:40 UTC

Conversa de Mercado

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 de fev. de 2026, 23:40 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 de fev. de 2026, 23:39 UTC

Aquisições, Fusões, Aquisições de Empresas

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 de fev. de 2026, 23:31 UTC

Ganhos

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 de fev. de 2026, 23:31 UTC

Ganhos

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 de fev. de 2026, 23:28 UTC

Ganhos

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 de fev. de 2026, 23:27 UTC

Ganhos

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 de fev. de 2026, 23:24 UTC

Conversa de Mercado

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 de fev. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 de fev. de 2026, 22:31 UTC

Ganhos

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 de fev. de 2026, 22:24 UTC

Ganhos

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy FY Underlying Ebitda A$700.9 Million

23 de fev. de 2026, 22:22 UTC

Ganhos

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 de fev. de 2026, 22:21 UTC

Ganhos

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 de fev. de 2026, 22:21 UTC

Ganhos

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 de fev. de 2026, 22:20 UTC

Ganhos

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparação entre Pares

Variação de preço

Microbot Medical Inc Previsão

Preço-alvo

By TipRanks

264.08% parte superior

Previsão para 12 meses

Média 7.5 USD  264.08%

Máximo 12 USD

Mínimo 5 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Microbot Medical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.52 / 2.57Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Very Strong Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat